insights_auto
Why is HCA down 2.96%?
Dive Deeperchevron_right
HCA:NYSE
HCA Healthcare Inc
$486.37
arrow_downward
-2.96%(-14.82) 1D
Nov 18, 11:20:03 AM GMT-5 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for HCA...
Open
$495.19
High
$498.78
Low
$484.97
Mkt. cap
101.53B
Avg. vol.
1.33M
Volume
234.01K
Dividend
0.64%
Quarterly dividend
$0.78
Ex-dividend date
Dec 15, 2026
P/E ratio
16.10
52-wk high
$556.52
52-wk low
$353.99
EPS
$30.19
Beta
1.11
Shares outstanding
208.89M
No. of employees
275K
Open
$495.19
High
$498.78
Low
$484.97
Mkt. cap
101.53B
Avg. vol.
1.33M
Volume
234.01K
Dividend
0.64%
Quarterly dividend
$0.78
Ex-dividend date
Dec 15, 2026
P/E ratio
16.10
52-wk high
$556.52
52-wk low
$353.99
EPS
$30.19
Beta
1.11
Shares outstanding
208.89M
No. of employees
275K
News stories
From web sources and news partners
News Corp
·
18 hours ago
HCA Healthcare Inc. stock outperforms competitors despite losses on the day
Zacks
·
1 day ago
Why HCA Healthcare (HCA) is a Top Stock for the Long-Term
Profile
HCA Healthcare, Inc. is an American global for-profit operator of health care facilities that was founded in 1968. It is based in Nashville, Tennessee, and, as of May 2020, owned and operated 186 hospitals and approximately 2,400 sites of care, including surgery centers, freestanding emergency rooms, urgent care centers and physician clinics in 20 states and the United Kingdom. As of 2024, HCA Healthcare is ranked #61 on the Fortune 500 rankings of the largest United States corporations by total revenue. In the 1990s, the company engaged in illegal accounting and other crimes that resulted in the payment of more than $2 billion in federal fines and other penalties, and the dismissal of the CEO Rick Scott by the board of directors. Wikipedia
About HCA Healthcare Inc
CEOSamuel N. Hazen
Employees275K
Founded1968
HeadquartersNashville, Tennessee, United States
SectorHealth Care
IndustryHealth care provider
Websitehcahealthcare.com
Analyst ratings
Based on 16 analysts giving stock ratings to HCA in the past 3 months
Buy
Buy
8
Hold
7
Sell
1
12-month forecast
Based on 16 Wall Street analysts offering 12 month price targets for HCA in the last 3 months.
Highest
Current $486.37
$570.00 (+17.19%)
Average
$469.31 (-3.51%)
Lowest
$380.00 (-21.87%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Benjamin Rossi J.P. Morgan | Hold | Maintained | $475.00 | -2.3% | 11/18/2026 |
Ann Hynes Mizuho Securities | Buy | Maintained | $570.00 | +17.2% | 11/15/2026 |
Kevin Fischbeck Bank of America Securities | Hold | Maintained | - | - | 11/05/2026 |
Lance Wilkes Bernstein | Hold | Maintained | $471.00 | -3.2% | 11/04/2026 |
Stephen Baxter Wells Fargo | Hold | Maintained | $468.00 | -3.8% | 11/02/2026 |
Ben Hendrix RBC Capital | Buy | Maintained | $521.00 | +7.1% | 10/29/2026 |
Andrew Mok CFA Barclays | Hold | Maintained | $401.00 | -17.6% | 10/29/2026 |
Ryan Langston TD Cowen | Buy | Maintained | $486.00 | -0.1% | 10/28/2026 |
Unknown Analyst Oppenheimer | Buy | Maintained | $485.00 | -0.3% | 10/28/2026 |
Sean Dodge BMO Capital | Buy | Reiterated | $495.00 | +1.8% | 10/28/2026 |
Michael Ha Robert W. Baird | Hold | Maintained | $409.00 | -15.9% | 10/28/2026 |
Matthew Gillmor CFA KeyBanc | Buy | Maintained | $490.00 | +0.7% | 10/28/2026 |
Craig Hettenbach Morgan Stanley | Sell | Reiterated | $380.00 | -21.9% | 10/29/2026 |
Andrew Cooper Raymond James | Hold | Reiterated | - | - | 09/28/2026 |
Whit Mayo Leerink Partners | Buy | Reiterated | - | - | 09/17/2026 |
Brian Tanquilut Jefferies | Buy | Maintained | $450.00 | -7.5% | 09/17/2026 |
Unknown Analyst Argus Research | Buy | Maintained | $500.00 | +2.8% | 08/07/2026 |
David Toung Argus Research | Buy | Reiterated | $500.00 | +2.8% | 08/07/2026 |
David S Macdonald Truist Financial | Buy | Reiterated | $495.00 | +1.8% | 08/05/2026 |
Scott Fidel Goldman Sachs | Buy | Maintained | $485.00 | -0.3% | 07/27/2026 |
A.J. Rice UBS | Buy | Maintained | $579.00 | +19% | 07/27/2026 |
Pito Chickering Deutsche Bank | Buy | Reiterated | $476.00 | -2.1% | 07/27/2026 |
Michael Wiederhorn Oppenheimer | Buy | Maintained | $485.00 | -0.3% | 07/27/2026 |
Sarah James Cantor Fitzgerald | Buy | Maintained | $525.00 | +7.9% | 07/14/2026 |
Unknown Analyst Stephens | Buy | Reiterated | $530.00 | +9% | 04/27/2026 |
Raj Kumar CFA Stephens | Buy | Reiterated | $530.00 | +9% | 04/27/2026 |
Courtney Breen Bernstein | Hold | Maintained | $541.00 | +11.2% | 03/30/2026 |
Last report
Oct 27, 2026
Fiscal period
Q3 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
$7.22 / $6.63
+8.95%beat
arrow_upward
Revenue / Est. (USD)
19.85B / 19.33B
+2.70%beat
arrow_upward
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
Revenue | 19.51B | 19.11B | 20.23B | 19.85B |
Cost of goods sold | 11.34B | 11.14B | 11.18B | 11.40B |
Cost of revenue | 11.34B | 11.14B | 11.18B | 11.40B |
Research and development expenses | - | - | - | - |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 1.03B | - | - | - |
Operating expense | 5.00B | 5.11B | 5.99B | 5.50B |
Total operating expenses | 16.34B | 16.25B | 17.16B | 16.90B |
Operating income | 3.18B | 2.86B | 3.07B | 2.94B |
Other non operating income | - | - | - | - |
EBT including unusual items | 2.67B | 2.29B | 2.49B | 2.37B |
EBT excluding unusual items | 2.63B | 2.29B | 2.48B | 2.36B |
Income tax expense | 509.00M | 430.00M | 564.00M | 521.00M |
Effective tax rate | 19.05% | 18.80% | 22.61% | 21.98% |
Other operating expenses | 3.06B | 4.18B | 5.04B | 4.55B |
Net income | 1.88B | 1.62B | 1.70B | 1.58B |
Net profit margin | 9.62% | 8.48% | 8.40% | 7.96% |
Earnings per share | 8.01 | 7.15 | 7.59 | 7.22 |
Interest and investment income | - | - | - | - |
Interest expense | -572.00M | -584.00M | -599.00M | -607.00M |
Net interest expenses | -572.00M | -584.00M | -599.00M | -607.00M |
Depreciation and amortization charges | 911.00M | 930.00M | 944.00M | 954.00M |
EBITDA | 4.09B | 3.79B | 4.01B | 3.90B |
Gain or loss from assets sale | -41.00M | 1.00M | -10.00M | -13.00M |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1
Upcoming events